A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2014
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors CASI Pharmaceuticals; EntreMed
- 19 Jan 2012 Actual patient number is 13 according to ClinicalTrials.gov.
- 19 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 19 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.